NFKB1 and osteoarthritis: Amurensin H has in vivo and in vitro anti‐inflammatory and chondroprotective effects and inhibits TLR4/Syk/NF‐κB signalling in chondrocytes, suggesting that amurensin H could be a potential candidate for disease‐modifying osteoarthritis drugs.